AKTX AKTX
Company Profile ↓Company Overview
AKTX (AKTX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -81.80% |
| 6 Months: | -19.53% |
| 3 Months: | +33.45% |
| 1 Month: | -51.55% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- Golden Cross3d ago
- RSI (14)35.60 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 83.3% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -1.88M | -2.33M | -218.03K | -1.65M | -1.46M | -23.33M | -3.85M | -4.59M | -4.62M | -2.51M | -5.99M | -7.45M | -2.93M | -3.52M | -3.12M | -7.40M | -15.76M |
| Net Income | -1.74M | -2.23M | -223.13K | -1.70M | -1.67M | -48.74M | -2.99M | 1.00M | -4.00M | -2.87M | -5.57M | -7.56M | -2.90M | -3.71M | -1.90M | -6.40M | -14.46M |
| Diluted EPS | - | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| R&D Expense | 800.00K | 1.54M | 162.57K | 1.55M | 142.00K | 1.31M | 1.50M | 1.73M | 1.52M | -314.00K | 2.28M | 3.31M | 143.00K | 813.00K | 667.00K | 249.00K | 1.46M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Income | -3.67M | -3.61M | -1.92M | -30.58M | -23.09M | -16.81M | -21.64M | -17.27M |
| Net Income | -4.27M | -3.62M | -1.95M | -45.32M | -17.75M | -10.01M | -19.79M | -17.30M |
| Diluted EPS | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 |
| R&D Expense | 1.48M | 1.28M | 1.62M | 5.80M | 9.56M | 5.45M | 6.98M | 2.81M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 7.83M | 3.39M | 69.89M | - | 13.83M | 4.36M | 50.56M | 47.89M |
| Total Equity | -2.48M | -3.36M | 400.69K | 2.22M | 48.72M | 5.55M | 1.79M | -229.00K | 22.23M | 28.33M |
| Cash & Equivalents | 6.00K | 1.10M | 553.65K | 3.33M | 68.92M | - | 13.25M | 3.85M | 0 | 0 |
| Total Liabilities | - | - | - | 1.17M | 21.17M | - | 12.04M | 4.58M | 28.33M | 19.56M |
| Current Liabilities | - | - | 1.23M | 1.17M | 21.12M | - | - | 4.58M | 19.91M | 12.35M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.13M | -5.45M | -1.48M | -4.97M | -21.50M | -16.43M | -12.55M | -10.57M |
| Investing Cash Flow | 0 | 0 | 0 | 1.39M | - | - | 382.00K | - |
| Financing Cash Flow | 3.23M | 12.00M | 4.24M | 69.04M | 25.29M | 7.02M | 10.99M | 13.17M |
| Capital Expenditure | -0 | -0 | -0 | -10.56K | - | - | - | - |
| Free Cash Flow | -2.13M | -5.45M | -1.48M | -4.98M | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - |
| ROE % | 127.0% | -903.4% | -87.6% | -93.0% | -991.0% | 4,370.3% | -89.0% | -61.1% |
| ROCE % | - | -54.6% | -86.3% | -62.7% | - | 7,338.9% | -70.6% | -48.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AKTX
Akari Therapeutics Stock Price Forecast. Should You Buy AKTX? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE1pT3ZjLXBHNnJEY0hZOWlIZGtQeDFRNVZoeDlqT1pfaUdmenBBY1FrSDcxc1ZIZ2pQU1NGU18wT09QdXVZM0xsMA?oc=5" target="_blank">Akari Therapeutics Stock Price Forecast. Should You Buy AKTX?</a>&nbs…
Akari Says Dual-Payload Strategy Could Broaden Therapeutic Activity - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPYm5tZnBQTFdnX09vYmh3akZvYWRhNHlLYWNRbmMtZGZUNHpVaGpYNUdaZk12Z1FsTTBZWUJ3ZEFWQmFpQ05xWnMxWHRZVzlDS0VwOVhZTnlROGZQZzdLWWI4TXpjRkpoWUxnVWVPenlHYTNyY1owQ3FjVnAyZ1QxMHBEYW9kZzFhSkdMSD…
AKTX Stock Goes Parabolic After Hours On $5.5M Capital Raise, Cancer Data Win: Wall Street Sees 400% Upside - Stocktwits
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxPX2VfaGpaU3N1Ml81X0VSN0ZFQVl2NDBEdy1xMjFvSEJxUzJ6Qng4VkZJc0lDdm1mZFpjRkljTnpuTjNZRGRUNEd1anEyd1FjT3lqQ0plNnpkc2dzMjRtOVJjZXFfa3BIZ19MUmZCMVZkVGVwZVlrbjBVQVhxVTFqQV85eGJEZkJ2dTNKcT…
Akari Therapeutics(AKTX) Stock Options Chain | Quotes & News - Moomoo
<a href="https://news.google.com/rss/articles/CBMiuANBVV95cUxNUnBFdW1HRHQ5OHRwcEc3TXBSaWI1V1EydlJLdk96Z0pJWlo2UGFyQUs2SGctQ3lQOEtudFlpcldxZGhWdmd0cnNURTRjdUc3MjJrVldNa1hPT2NrYUpwTzcwZnVCajA2cDlBZ2c4SGRlM19FbHBXU1N4ZmRCcUc3Mm41bTJ3djFPb3VrQk…
Akari Therapeutics (AKTX) surges as new KRAS pancreatic cancer data and a $5.5M financing grab investor attention - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxPNFFuQTlMeWNFandpN1dITUNYZFhCTVRhNDl0UF9QZldJdEZJZjk4cWF0NEw5U0xuRDBwSURkQXMxYkpxT0t5cU9Venk0TTUzWGVZMk10bDBOdWlUUm5hNUs1SnVUWF9rbGZlaTFlOS1zOGRJVGdELUpiNk92bTQyd3hkNy1TVHFKaXh6Uk…
Akari Therapeutics Plc Revenue Breakdown – NASDAQ:AKTX - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTFAzLTJmYjV4WmZlZ2QtcmFjYXoyTDRrNzRTc3EzM2NHTnE4RDEydVpQV1hvcmlkeUYtWWdhUm9iNC0wMUduY3VvQ0FOTjdqRmJ1ZGc4SHpHa1dabHlPdlB2bEVMaEpyclVFSVN1SHNITVZNdjQ2OW0w?oc=5" target="_blank">Akari T…
AKTX — Frequently Asked Questions
What is the current share price of AKTX?
As of 2026-08-05 17:25 PDT, AKTX trades at $7.50 on NASDAQ/NYSE. Its 52-week range is $3.06 to $44.80.
What is the return on equity (ROE) of AKTX?
AKTX has a return on equity (ROE) of -61.06%. Its return on capital employed (ROCE) is -48.61%.
Is AKTX a good stock to buy?
This page provides a data-driven analysis of AKTX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.